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Metastasis-associated macrophages (MAMs) play pivotal roles in breast cancer 
metastasis by promoting extravasation and survival of metastasizing cancer cells. In 
a metastatic breast cancer mouse model, we previously reported that circulating 
classical monocytes (C-MOs) preferentially migrated into the tumor-challenged lung 
where they differentiated into MAMs. However, the fate and characteristics of C-MOs 
in the metastatic site has not been defined. In this study, we identified that adoptively 
transferred C-MOs (F4/80lowCD11b+Ly6C+) differentiated into a distinct myeloid cell 
population that is characterized as F4/80highCD11bhighLy6Chigh and gives rise to MAMs 
(F4/80lowCD11bhighLy6Clow) within 18 h after migration into the metastatic lung. In mouse 
models of breast cancer, the CD11bhighLy6Chigh MAM precursor cells (MAMPCs) were 
commonly found in the metastatic lung, and their accumulation was increased during 
metastatic tumor growth. The morphology and gene expression profile of MAMPCs 
were distinct from C-MOs and had greater similarity to MAMs. For example MAMPCs 
expressed mature macrophage markers such as CD14, CD36, CD64, and CD206 at 
comparable levels with MAMs, suggesting that MAMPCs have committed to a macro-
phage lineage in the tumor microenvironment. MAMPCs also expressed higher levels 
of Arg1, Hmox1, and Stab1 than C-MOs to a comparable level to MAMs. Expression 
of these MAM-associated genes in MAMPCs was reduced by genetic deletion of colo-
ny-stimulating factor 1 receptor (CSF1R). On the other hand, transient CSF1R blockade 
did not reduce the number of MAMPCs in the metastatic site, suggesting that CSF1 
signaling is active in MAMPCs but is not required for their accumulation. Functionally 
MAMPCs suppressed the cytotoxicity of activated CD8+ T cells in vitro in part through 
superoxide production. Overall, our results indicate that immediately following migration 
Abbreviations: C-MO, classical monocyte; NC-MOs, non-classical monocytes; TAM, tumor-associated macrophage; MDSC, 
myeloid-derived suppressor cell; MAM, metastasis-associated macrophage; MAMPC, MAM progenitor cell; RMAC, resident 
macrophage; CSF1R, colony-stimulating factor 1 receptor; PyMT, polyoma middle T oncoprotein; ROS, reactive oxygen spe-
cies; SOD, superoxide dismutase.
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into the metastatic tumors C-MOs differentiate into immunosuppressive cells that have char-
acteristics of monocytic myeloid-derived suppressor cell phenotype and might be targeted 
to enhance efficacy of immunotherapy for metastatic breast cancer.
Keywords: breast cancer, metastasis, macrophage, myeloid-derived suppressor cell, immune suppression, cD8+ T cell
inTrODUcTiOn
Breast cancer is the most common cancer in women worldwide, 
accounting for 23% of the total new cancer cases (1). The mortality 
rate of breast cancer has been decreasing due to the development 
of early detection techniques and improvement in treatment (1). 
However, breast cancer cells frequently metastasize to the bone 
and lung, which dramatically reduces 5-year survival of breast 
cancer patients to less than 25% (2). Indeed, data show that 
survival of metastatic breast cancer patients has not significantly 
improved over the past 30  years (3). This depressing statistic 
indicates the requirement of novel approaches that efficiently 
block metastatic tumor development.
Attractive targets for improvements in therapy are tumor- 
infiltrating immune cells such as regulatory T cells, tumor-associated 
neutrophils, myeloid-derived suppressor cells (MDSCs), and 
tumor-associated macrophages (TAMs), as these cells play pivotal 
roles in the establishment of metastatic tumors (4). In particular, 
TAMs have been shown to be critical promoters of metastatic breast 
cancer development following early experiments that showed 
marked suppression of tumor progression and metastasis by genetic 
macrophage depletion in a mouse model of breast cancer in which 
mammary tumors are caused by the mammary epithelial restricted 
polyoma middle T oncoprotein (PyMT) expression (5). In addi-
tion, many studies have correlated poor prognosis of breast cancer 
patients with high infiltration of TAMs into the tumor (6). Data 
from mouse models of metastatic breast cancer have also defined 
mechanisms of this metastasis promotion indicating that TAMs 
support tumor cell invasion and intravasation at the primary sites 
(7), enhance angiogenesis (8), transmit survival signals to the meta-
stasizing tumor cells (9), and promote extravasation and persistent 
growth of tumor cells at the metastatic site (10). In addition, there is 
preliminary evidence that TAMs are involved in immunosuppres-
sion. For example, TAMs express high levels of programmed death 
ligand 1 (PD-L1), a ligand for immune-checkpoint receptor that 
restricts CD8+ T cell activities (11, 12), and the targeting of TAMs 
improves efficacy of the check-point inhibitors in a pancreatic 
ductal carcinoma model in mice (13). It is also reported that TAMs 
suppress CD8+ T cell-mediated anti-tumor immunity in the mam-
mary tumor of PyMT mice under treatment with chemotherapy 
(14). Therefore, TAMs represent important potential therapeutic 
target to treat metastatic breast cancer (4).
One of the most extensively explored strategies to target TAMs 
is the inhibition of colony-stimulating factor 1 receptor (CSF1R) 
(12). Antagonists or blocking antibodies against CSF1R suppress 
the accumulation of TAMs as well as changing their phenotype, 
enhance CD8+ T  cell-mediated antitumor immune responses, 
and prevent disease progression or primary tumor growth in 
mouse models of glioblastoma, pancreatic, colon, and breast can-
cer (13–16). These data based on genetically engineered mouse 
models of the primary tumor suggest that TAM intervention by 
CSF1R inhibition is an attractive strategy to block environmental 
support for malignant tumor development and to improve thera-
peutic efficacy of CD8+ T cell-based immunotherapy.
For therapeutic TAM intervention aimed at blocking the meta-
static tumor expansion, a better understanding of macrophages in 
the metastatic sites is important since macrophages change their 
phenotypes in response to environmental factors and these 
might be different between the primary and metastatic tumors 
(17). In mouse models of metastatic breast cancer, there are at 
least two distinct macrophage populations characterized as 
F4/80+CD11blowCD11chigh and F4/80+CD11bhighCD11clow in the 
lung with metastatic tumors (10). The CD11chigh macrophage 
population consists of alveolar macrophages that also exist in 
the normal lung (18, 19). In contrast, the CD11bhigh macrophages 
markedly accumulate in the tumor-challenged lung but are 
significantly less in the normal lung (10). In an experimental 
metastasis model using Met-1 mouse breast cancer cells on a FVB 
genetic background, depletion of these CD11bhigh metastasis-
associated macrophages (MAMs) but not CD11chigh resident 
macrophages (RMACs) reduces the number and size of meta-
static foci (10). In this model, a subset of monocytes characterized 
as CD11b+Ly6C+ [classical monocytes (C-MOs)] preferentially 
migrates to the tumor-challenged lung via a chemokine receptor 
CCR2, and inhibition of their recruitment results in the reduc-
tion of the number of MAMs (CD11bhighLy6Clow) and metastatic 
tumor load in the lung (20). In another experimental metastasis 
model using E0771-LG mouse breast cancer cells on a C57BL/6 
background, adoptively transferred CD11b+Ly6C+ C-MOs differ-
entiate to a CD11bhighLy6Clow population within 42 h posttransfer 
(21). Although a minor macrophage population in the normal 
lung called interstitial macrophages is also characterized as 
CD11b+CD11clow (18, 19), these cells are not rapidly replenished 
by C-MOs (22) and their accumulation by bacterial CpG DNA 
does not require CCR2 (23). Collectively, these data indicate that 
the circulating C-MOs differentiate into MAMs at the metastatic 
sites, which promotes the establishment of metastatic tumors. 
Therefore, C-MOs in the differentiation process at the meta-
static site can be a novel therapeutic target for the treatment of 
metastatic breast cancer, and thus it is important to understand 
their dynamics and characteristics after infiltrating the metastatic 
tumors.
In this article, we have identified that circulating C-MOs dif-
ferentiate into a distinct myeloid cell population characterized 
as CD11bhighLy6Chigh in the metastatic lung where they further 
differentiate into MAMs. The CD11bhighLy6Chigh MAM precursor 
cells (MAMPCs) expressed mature macrophage markers, and 
their gene expression profile was similar with that of MAMs but 
distinct from C-MOs. We also found that accumulation of the 
CD11bhighLy6Chigh cells was increased when micro-metastasis 
started to outgrow, and was not suppressed by blockade of CSF1R. 
We further identified that the MAMPCs suppressed cytotoxic 
3Kitamura et al. Immunosuppressive Macrophage Precursors in Metastasis
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 8 | Article 2004
ability of CD8+ T cells through reactive oxygen species (ROS)-
mediated but checkpoint ligands-independent mechanism. These 
results indicate that C-MOs recruited to the metastatic tumors 
produce immune suppressive precursor MAMs that may not be 
targeted by CSF1R antagonists or checkpoint inhibitors.
MaTerials anD MeThODs
Mice
MMTV-PyMT mice (24) on the C57BL/6 background were 
obtained from Dr. Sandra J. Gendler (Mayo Clinic College of 
Medicine) who had backcrossed PyMT mice established by Dr. 
William J Muller (McGill University, Montreal, Canada) origi-
nally on the FVB background. To analyze the lung with metastatic 
tumors, we used female PyMT mice on the C57BL/6 background 
at 20–25  weeks of age. Csf1r-EGFP (MacGreen) (25) mice on 
the C57BL/6 background were obtained from Dr. David Hume 
(University of Edinburgh). Conditional CSF1R knockout (Csf1r 
cKO) mice (i.e., rtTA:tetO-Cre:Csf1rF/F) were obtained by cross-
ing the B6.Cg-Csf1rtm1Jwp/J (Csf1rF/F) mice (26) with ROSA-rtTA 
and tetO-Cre mice (Jackson lab) (21). Animals were housed and 
bred under standard conditions of care. All procedures involving 
mice were conducted in accordance with licensed permission 
under the UK Animal Scientific Procedures Act (1986) (Home 
Office license number PPL 70/8065) and Institutional Animal 
Care & Use Committee of the Albert Einstein College of Medicine 
(20120304).
Tumor cell lines
Met-1 mouse mammary tumor cells derived from the MMTV-
PyMT tumor in FVB mice (27) and highly metastatic derivative 
of E0771 mouse mammary adenocarcinoma cells derived from a 
medullary cancer in C57BL/6 mice (E0771-LG) (21) were cultured 
in DMEM supplemented with 10% v/v FBS, 100 U/mL penicillin, 
and 100 µg/mL streptomycin. E0771-LG cells were manipulated 
to express firefly luciferase (E0771-LG:Fl) or nuclear localized 
red fluorescent protein (mKate) (E0771-LG:NLR) to detect the 
cells by in vivo bioluminescence imaging or in vitro fluorescence 
microscopy, respectively. We have confirmed that all cells were 
negative for mycoplasma.
Breast cancer Metastasis Models in Mice
As experimental models of metastatic breast cancer, we injected 
1 × 106 of E0771-LG or Met-1 cells into the tail vein of C57BL/6 
or FVB mice (7-week-old female), respectively. At 7–14  days 
(E0771-LG) or 21  days (Met-1) posttumor cell injection, we 
euthanized the mice and isolated the blood and lung to prepare 
samples for flow cytometry or H&E staining.
In Vivo Bioluminescence imaging
We intraperitoneally injected d-luciferin in PBS (GoldBio, 
1.5 mg/100 μL/20 g mouse) into anesthetized E0771-LG:Fl tumor-
bearing mice. Bioluminescence from the luciferase-expressing tumor 
cells was imaged using Photon Imager Optima (Biospace Lab), and 
photon counts (photon/second/cm2/sr) in the lung area were quanti-
fied by image analysis software (M3 Vision, Biospace Lab).
adoptive Transfer of Monocytes
We isolated C-MOs from the bone marrow of MacGreen mice by 
Monocyte Isolation Kits (Miltenyi). 5 × 105 of the GFP+ C-MOs 
were transferred into C57BL/6 mice that have received intrave-
nous injection of E0771-LG:Fl cells. Pulmonary tumor burdens in 
the recipient mice were determined by bioluminescence imaging 
1 day before monocyte transfer (10 days after tumor injection). 
Eighteen, 42, 66, or 90 h after the C-MO transfer, we euthanized 
the animals and isolated the blood and lung for flow cytometry.
Flow cytometry and sorting
Single-cell suspensions from perfused lungs were prepared via 
enzymatic digestion using the Lung Dissociation Kit (Miltenyi) 
and following filtration through a 40 µm cell strainer. Red blood 
cells in the lung digestions and blood samples were removed using 
RBC lysis buffer (Biolegend). The samples were blocked with 
antimouse CD16/CD32 antibody (BD bioscience), and stained 
with DAPI and fluorescent antibodies to following antigens; 
CD45 (30-F11), F4/80 (BM8), CD11b (M1/70), Ly6C (HK1.4), 
CD115 (AFS98), Ly6G (1A8), CD11c (N418), CD14 (Sa14-2), 
CD36 (HM36), CD64 (X54-5/7.1), CD206 (C068C2), CCR5 
(HM-CCR5), PD-L1 (10F.9G2), CD80 (16-10A1), CD86 (GL-1) all 
from Biolegend, and PD-L2 (122) from eBioscience. Flow cytom-
etry was performed using LSRII cytometer (BD Biosciences) and 
analyzed using Flowjo software (TreeStar). In some experiments, 
the stained C-MOs (CD115+Ly6G−CD11b+Ly6Chigh) in the blood 
or bone marrow, MAMPCs (F4/80+Ly6G−CD11bhighLy6Chigh), 
MAMs (F4/80+Ly6G−CD11bhighLy6Clow), and RMACs 
(F4/80+Ly6G−CD11blowLy6Clow) in the lung of E0771-LG-injected 
mice were sorted using FACS Artia II (BD Biosciences).
Microarray analysis
We sorted C-MOs from the bone marrow and MAMPCs and 
MAMs from the lung with E0771-LG metastatic tumors (N = 3 
per group) as described above. We extracted RNA from these cells 
by RNeasy Micro Kit (Qiagen) and used this for hybridization 
on Affymetrix MoGene 2.0 ST chip. Datasets were annotated 
and normalized using the robust multichip average algorithm 
(rma) from the GenePattern platform. All statistical calculations 
were performed in R programming language (version 3.2.3). The 
dataset was analyzed using the oligo package from Bioconductor. 
Multiple probes were collapsed to single gene using the average 
expression (avereps function). Using the Limma package, a linear 
model was fitted for the identification of differentially expressed 
genes. Genes with FDR ≤ 0.05 and log2FC ≥ +1.0 (upregulated) or 
log2FC ≤ −1.0 (downregulated) are considered to be differentially 
expressed. Venn diagrams were drawn using the differentially 
expressed genes between the populations. Heat maps were drawn 
using the gplots package on the differentially expressed genes 
between MAMPC and C-MO populations. A clustering method 
was set to complete and distance measure to Pearson correlation.
real-time Quantitative rT-Pcr analysis
We isolated total RNA from C-MOs, MAMPCs, MAMs, and 
RMACs as described above, and performed reverse transcription 
using oligo(dT)18 primers with SuperScript III (Invitrogen). 
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Real-time quantitative PCR was performed using SYBR master 
mix (Invitrogen) on the Applied Biosystems 7500 Real-Time PCR 
System (Applied Biosystems) by the following program: preheat-
ing at 95°C for 10 min, 40 cycles of amplification consisting of 15 s 
denaturing at 95°C, 30 s annealing at 61°C, and 20 s extension at 
72°C. Relative expression of target genes was determined according 
to ΔΔCt with normalization to Gapdh expression. Primers used for 
PCR were: Adm, 5′-CACCCTGATGTTATTGGGTTCA-3′ and 
5′-TTAGCGCCCACTTATTCCACT-3′; Arg1, 5′-CTCCAAGCC 
AAAGTCCTTAGAG-3′ and 5′-AGGAGCTGTCATTAGGGAC 
ATC-3′; Cd163, 5′-GGTGGACACAGAATGGTTCTTC-3′ and 
5′-CCAGGAGCGTTAGTGACAGC-3′; Hmox1, 5′-AAGCCGA 
GAATGCTGAGTTCA-3′ and 5′-GCCGTGTAGATATGGTACA 
AGGA-3′; Mrc1, 5′-CTCTGTTCAGCTATTGGACGC-3′ and 
5′-CGGAATTTCTGGGATTCAGCTTC-3′; Stab1, 5′-GGCAG 
ACGGTACGGTCTAAAC-3′ and 5′-AGCGGCAGTCCAGAA 
GTATCT-3′; Gapdh, 5′-AGAACATCATCCCTGCATCC-3′ and 
5′-CACATTGGGGGTAGGAACAC-3′.
Blockade of csF1 receptor
For genetic depletion of CSF1 receptor, we gave doxycycline 
(SIGMA, 20 mg/mL) in drinking water with 5% w/v sucrose to 
the rtTA:tetO-Cre:Csf1rF/F (Csf1r cKO) mice from 7  days after 
tumor injection to the endpoint. For pharmacological CSF1R 
inhibition, we gave BLZ945 (Selleckchem, 4 mg/20 g mouse, oral 
gavage) from 7 days after tumor injection to the endpoint.
In Vitro cD8+ T cell cytotoxicity assay
We isolated CD8+ T  cells from the spleen of C57BL/6mice 
by EasySep Mouse CD8+ T Cell Isolation Kit (Stemcell 
technologies). 1 ×  105 of CD8+ T  cells were cultured with or 
without 1  ×  105 of MAMPCs, MAMs, or RMACs from the 
E0771-LG tumor-bearing lung in enriched DMEM (20% v/v 
FBS, 2  mM l-glutamine, 1% v/v non-essential amino acid, 
1  mM sodium pyruvate, 50  nM 2-mercaptoethanol, 100  U/
mL penicillin, 100  µg/mL streptomycin) containing 80  U/
mL IL-2, 2  µg/mL anti-CD3ε (145-2C11, Biolegend), and 
5  µg/mL anti-CD28 (37.51, Biolegend). In some experiment, 
we added NG-Methyl-l-arginine acetate salt (L-NMMA, 
SIGMA, 500  µM), Nω-hydroxy-nor-arginine (nor-NOHA, 
Cambridge Bioscience, 500  µM), catalase (SIGMA, 1,000  U/
mL), and superoxide dismutase (SOD, SIGMA, 200  U/mL) 
into the culture. After 4  days, CD8+ T  cells (non-adherent) 
were collected and resuspended in enriched DMEM including 
1,000 U/mL IL-2. The activated CD8+ T cells (effector) were then 
cocultured with 1 × 103 of E0771-LG:NLR cells (target) at differ-
ent effector/target ratio in the presence of fluorogenic caspase-3 
substrate (NucView488, Biotium) in 96-well plates coated with 
basement membrane extract (Geltrex, Gibco). The cultured 
cells were imaged by IncuCyte Zoom Live-Cell Analysis System 
(Essen Bioscience) for 48  h, and number of apoptotic cancer 
cells (red/green double positive) were counted using IncuCyte 
S3 software.
statistical analysis
Sample size was determined for power based on a relative SD from 
our previous studies. All samples were collected independently 
and analyzed by at least two independent experiments. Data were 
analyzed by Student’s t-test and are expressed as mean ± SEM. 
P-values <0.05 were considered significant.
resUlTs
c-MO Differentiate into a Distinct 
Population That gives rise to MaMs  
in the Metastatic site
To understand the fate of C-MOs in the metastatic sites, we 
utilized MacGreen mice on a C57/BL6 background in which 
myeloid cells including monocytes and macrophages express 
green fluorescent protein (GFP) under the regulation of the 
CSF1R promoter (25). We transferred purified C-MOs from 
MacGreen mice into the C57BL/6 mice that have developed 
metastatic tumors in the lung following injection of E0771-LG 
mouse breast cancer cells that colonize the lung and form meta-
static tumors. We tracked the fate of the GFP+ cells in the blood 
and lung at 18, 42, 66, and 90 h postinjection (Figure 1A). Since 
it was impractical to collect significant numbers of monocytes 
from peripheral blood, we isolated the C-MOs from the bone 
marrow that were characterized as CD11b+Ly6C+CD115+ but 
did not express markers for neutrophils (Ly6G) or hemat-
opoietic stem/progenitor cells (c-Kit and Sca-1) (Figure S1 in 
Supplementary Material). By 18 h posttransfer, almost all GFP+ 
cells in the blood remained in a CD11b+Ly6C+ population that is 
characteristic for the C-MOs (Figures 1B,C). In contrast, GFP+ 
cells in the metastatic lung expressed higher levels of CD11b and 
Ly6C and a majority of them were found as a CD11bhighLy6Chigh 
population distinct from the GFP+ cells and the intrinsic C-MOs 
in blood (Figures 1B,C). By 42 h after transfer, the GFP+ cells 
in the metastatic lung still expressed higher level of CD11b than 
C-MOs. However, more than half of cells had reduced Ly6C 
expression and thereby shifted to a CD11bhighLy6Clow population 
that resembles the phenotype of MAMs (10). The ratio of the 
CD11bhighLy6Clow population increased by 90  h after transfer, 
and that of CD11bhighLy6Chigh population concomitantly reduced 
(Figures  1B,C), indicating that CD11bhighLy6Chigh GFP+ cells 
are progenitors of MAMs. Interestingly around 15% of GFP+ 
cells in the lung after 90  h were outside the CD11bhighLy6Clow 
gate probably due to the reduction in their CD11b expression 
(Figure  1B). In our model, the transferred C-MOs in the 
blood became non-classical monocytes (NC-MOs) character-
ized as CD11b+Ly6Clow by 42  h posttransfer (Figure S2 in 
Supplementary Material) consistent with previous studies (28). 
However, these cells were distinct from the GFP+ cells in the lung 
that were characterized as CD11bhighLy6Clow. The GFP+ cells in 
the metastatic lung expressed higher levels of F4/80 and major 
histocompatibility complex II (MHC-II) than GFP+ cells in the 
blood and intrinsic C-MOs (Figure 1D), suggesting their com-
mitment to a macrophage lineage. Given their low expression of 
CD11c and Ly6G, these cells were distinct from RMACs, den-
dritic cells, or neutrophils (Figure 1D). As shown in Figure 1E, 
the CD11bhighLy6Chigh population was also found in the intrinsic 
F4/80+ cells that accumulated in metastatic lungs, indicating that 
their presence is not an artifact of adoptive transfer. Although 
FigUre 1 | Adoptively transferred classical monocytes (C-MOs) differentiate into a distinct myeloid population that gives rise to metastasis-associated 
macrophages (MAMs) in the metastatic site. (a) A scheme of the monocyte tracking experiment (left) and representative dot plots showing the transferred (GFP+) 
and intrinsic (GFP−) cells in the blood and lung of the tumor-bearing monocyte-transferred mouse (right). (B) Representative dot plots showing expression of CD11b 
and Ly6C in the transferred GFP+ cells in the blood and lung of tumor-bearing mice after the indicated time posttransfer (n = 3/group, two independent 
experiments). Three typical populations characterized as CD11b+Ly6C+ (green), CD11bhighLy6Chigh (blue), and CD11bhighLy6Clow (red) were shown. (c) Percentage is 
shown of CD11b+Ly6C+, CD11bhighLy6Chigh, and CD11bhighLy6Clow populations in GFP+ cells (n = 3/group, two independent experiments). Data are mean ± SEM, 
*P < 0.01 vs. blood 18 h (BL-18 h), #P < 0.01 vs. lung 18 h (Lg-18 h). (D) Representative histograms showing expression of indicated markers in the transferred 
GFP+ cells in the blood and lung as well as GFP+ cells before transfer (before). As a control, expressions of markers in intrinsic cells from the tumor-bearing mouse 
are shown in the bottom. C-MO, non-classical monocytes (NC-MO), and neutrophils (Neu) were identified in blood, and CD11bhighLy6Chigh cells (Ly6Chi), MAM, and 
resident macrophages (RMAC) were detected in the metastatic lung. Data are representative of two independent experiments with three mice per group.  
(e) Representative dot plots showing expression of CD11b and Ly6C in the intrinsic CD115+Ly6G− cells in the blood and F4/80+Ly6G− cells in the lung from the 
E0771-LG-injected C57BL/6 mice used in (B) (n = 3, two independent experiments). Three typical populations characterized as C-MO (green), NC-MO (orange), 
CD11bhighLy6Chigh (blue), MAM (red), and RMAC (purple) were shown.
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the CD11bhighLy6Chigh cells might be considered as monocytes, 
their expression of CD11b, Ly6C, F4/80, and MHC-II clearly 
distinguish them from circulating C-MOs (Figures  1B,D,E). 
Collectively, these results indicate that circulating C-MOs 
differentiate to MAMPCs characterized as CD11bhighLy6Chigh 
once they migrate to the metastatic site. Hereafter we call the 
CD11bhighLy6Chigh cells MAMPCs.
MaMPc accumulation in Metastatic sites 
is increased during Metastatic Tumor 
Outgrowth
To investigate whether the MAMPCs accumulate in spontane-
ous pulmonary metastases, we analyzed lung metastatic lesions 
in PyMT mice on C57BL/6 background. Consistent with our 
FigUre 2 | CD11bhighLy6Chigh metastasis-associated macrophage (MAM) precursor cells (MAMPCs) accumulate in the lung during metastatic tumor growth.  
(a) Representative dot plots of the lung of normal C57BL/6 and BL6;PyMT mice that have established metastatic tumors (n = 3, three independent experiments). Cells 
were first gated as CD45+F4/80+, and then MAMPCs (blue), MAMs (red), and resident macrophages (RMACs) (purple) were defined as CD11bhighLy6Chigh, 
CD11bhighLy6Clow, and CD11b−Ly6Clow, respectively. (B) Relative numbers of MAMPCs, MAMs, and RMACs in the lung of C57BL/6 and metastasis-bearing PyMT mice 
(n = 3, three independent experiments). Data are mean ± SEM, *P < 0.05. (c) Representative dot plots of the lung from normal and metastasis-bearing FVB mice at 
21 days after intravenous injection of Met-1 mouse mammary tumor cells (n = 3, two independent experiments). Cells were gated as described in (a). (D) Relative 
numbers of MAMPCs, MAMs, and RMACs in the normal and Met-1 tumor-bearing (Met-1) lung at 21 days after tumor injection (n = 3, two independent experiments). 
Data are mean ± SEM, *P < 0.05. (e) Representative H&E-stained lung sections from normal C57BL/6 mice and from those transplanted with E0771-LG cells 7 or 
14 days before isolation of the lung. Scale bar; 200 µm. (F) Relative numbers of cells with the phenotypes of MAMPCs, MAMs, and RMACs in the lung of normal  
(N, n = 4) and tumor-injected mice at days 7 and 14 post-E0771-LG injection mice (n = 3, two independent experiments). Data are mean ± SEM, *P < 0.05.
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results using transferred cells (Figure 1B), we found that F4/80+ 
cells in the spontaneous metastatic lung but not in the normal 
lung included a CD11bhighLy6Chigh population (i.e., MAMPCs) 
that is distinct from MAMs (CD11bhighLy6Clow) and RMACs 
(CD11blowLy6Clow) (Figure 2A). The relative numbers of MAMPCs 
as well as MAMs were significantly higher in the metastatic lung 
compared with the normal lung (Figure 2B), whereas the ratio of 
RMACs was relatively low due to the recruitment of myeloid cells 
to the tumors. We also analyzed another metastatic breast cancer 
model, i.e., FVB mice intravenously injected with Met-1 mouse 
mammary tumor cells (27). Consistent with the other two mod-
els, we found a significant increase in the numbers of MAMPCs 
and MAMs in the lung with metastatic tumors compared with 
normal lung (Figures  2C,D), suggesting that accumulation of 
the CD11bhighLy6Chigh MAMPCs in the metastatic site is not a 
model-dependent artifact. To understand the timing of MAMPC 
accumulation in the metastatic lung, we utilized the experimental 
metastasis model using E0771-LG cells in which intravenously 
transplanted cancer cells reproducibly develop micro-metastases 
in the lung by day 7 that subsequently grow into macro-metastatic 
lesions by day 14 (Figure 2E). We found that the ratio of cells in 
the MAMPC gate increased by day 7 and further increased by 
day 14 (Figure 2F). Similarly, accumulation of cells in the MAM 
gate but not RMACs was increased when metastatic tumors grow 
in the lung (Figure  2F). Taken together, these results indicate 
that accumulation of MAMPCs is associated with the metastatic 
tumor outgrowth in mouse models of metastatic breast cancer.
Morphology and gene Profile of MaMPcs 
are Distinct from c-MOs but similar  
to MaMs
To further characterize MAMPCs, we analyzed the morphology 
of cells isolated by gating C-MOs, MAMPCs, and MAMs from 
FigUre 3 | The metastasis-associated macrophage (MAM) precursor cells (MAMPCs) are morphologically and transcriptionally distinguishable from classical 
monocytes (C-MOs) and MAMs. (a) Representative morphology of C-MOs in the blood, and MAMPCs and MAMs in the lung of mice with E0771-LG metastatic 
tumors. Scale bar; 10 µm. The number of cells with the indicated morphology in the total counted cells is shown. (B) Unsupervised multidimensional scaling (MDS) 
plot of the normalized gene expression of RNA isolated from C-MOs, MAMPCs, and MAMs (n = 3/group). C-MOs were isolated from the bone marrow and 
MAMPCs and MAMs were isolated from the lung of mice bearing E0771-LG metastatic tumors. (c) Unsupervised hierarchical clustering of differentially expressed 
genes (FDR < 0.05) between MAMPC and C-MO populations. Columns indicate samples, rows indicate genes, and color intensity represents the Z-score-
transformed RNA expression values. Samples are clustered using complete linkage and Pearson correlation. (D) Venn diagram of the commonly regulated genes in 
MAMPCs compared with C-MOs or MAMs (log2FC more or less than −1/1, FDR = < 0.05). (e) Genes encoding macrophage receptors that were upregulated in 
MAMPCs (blue) and MAMs (red) compared with IMs (logFC > 1, P < 0.01). Genes were clustered according to their ligands, i.e., phosphatidylserine receptors 
(Havcr2, Mertk), complement receptors (C3ar1, C5ar1, ItgaX), Toll-like receptors and coreceptor (Tlr3, Tlr5, Cd14), C-type lectin (Clec4e), scavenger receptors 
(Cd36, Marco, Mrc1, Stab1), cytokine and chemokine receptors (Ilr1, Cd40, Tnfsf11a, Tnfsf12a, Ccr5), and Fc receptors (Fcgr1, Fcgr4). Data on expression values 
are presented as mean ± SEM. Note that the scale is exponential. (F) Representative histogram (top) and mean fluorescent intensity (bottom) of indicated proteins  
in C-MOs, MAMPCs, and MAMs (n = 3, two independent experiments). Blood (for C-MOs) and lung digestion (for MAMPCs and MAMs) were prepared from 
E0771-LG-injected C57BL/6 mice at 14 days posttumor injection and stained with antibodies for indicated markers or isotype IgG. Data are mean ± SEM, 
*P < 0.01 vs. C-MO, #P < 0.01 vs. MAMPC.
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the blood and lung of mice that have developed metastatic tumors 
by E0771-LG cells but have not received monocyte transfer. Most 
of the cells sorted by C-MO gate from the blood (126/154, 88%) 
showed the typical morphology of monocytes (Figure 3A), i.e., 
bi-lobate nucleus and a cytoplasm devoid of granules (29). In 
contrast, the majority of the cells sorted by MAMPC gate from 
the metastatic lung (412/489, 84%) were distinguishable from 
C-MOs by their larger cellular size (6.7 ± 0.05 and 5.7 ± 0.05 μm 
in diameter for MAMPCs and C-MOs, respectively, P < 0.01) and 
a vacuolated cytoplasm (Figure 3A), whereas a minority of them 
showed a similar morphology with C-MOs (25/489, 5%). Cells 
with cytoplasmic vacuoles were rarely found in the C-MO gate 
(10/154, 6%). In contrast, the majority of cells sorted by the MAM 
gate from the metastatic lung (1,300/1,633, 80%) had vacuoles in 
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their cytoplasm. More than half of these vacuolated cells in MAM 
gate (792/1,300, 61%) were larger than MAMPCs (8.7 ± 0.05 μm 
and 6.7 ± 0.05 in diameter for MAMs and MAMPCs, respectively, 
P < 0.01), whereas 39% (508/1,300) of cells were comparable in 
size (6.2 ± 0.05 μm) with MAMPCs (Figure 3A). These results 
suggest that MAMPCs are in an intermediate stage of differentia-
tion from C-MOs to MAMs.
To identify similarity and difference between C-MOs, MAMPCs, 
and MAMs we compared gene expression profiles of these cells 
by microarray analysis. To obtain sufficient cells, C-MOs were 
isolated from the bone marrow. Unsupervised multidimensional 
scaling plot of all expressed genes showed distinct clusters of the 
three populations, suggesting that MAMPCs are a distinct cell 
type from C-MOs and MAMs (Figure 3B). On the other hand, 
differential expression analysis and hierarchical clustering showed 
that there were fewer differentially expressed genes between 
MAMPCs and MAMs compared to C-MOs (Figures 3C,D; Table 
S1 in Supplementary Material), suggesting the phenotypic similar-
ity between MAMPCs and MAMs. The array data also indicated 
that MAMPCs and MAMs both expressed higher levels of key 
macrophage receptor genes (30) than C-MOs, which included 
genes encoding phosphatidylserine receptors (Havcr2, Mertk), 
complement receptors (C3ar1, C5ar1, ItgaX), Toll-like recep-
tors and coreceptor (Tlr3, Tlr5, Cd14), C-type lectin (Clec4e), 
scavenger receptors (Cd36, Marco, Mrc1, Stab1), cytokine and 
chemokine receptors (Ilr1, Cd40, Tnfsf11a, Tnfsf12a, Ccr5), and 
Fc receptors (Fcgr1, Fcgr4) (Figure 3E). To validate the array data, 
we determined expression of these receptors by flow cytometry in 
C-MOs from the blood and MAMPCs and MAMs from the lungs 
of mice with metastatic tumors. We confirmed that MAMPCs and 
MAMs in the metastatic lung expressed significantly higher levels 
of CD14, CD36, CD64 (Fcgr1), CD206 (Mrc1) and CCR5 proteins 
compared with circulating C-MOs in the tumor-bearing mice 
(Figure 3F). Expression of other receptors could not be analyzed 
due to the lack of reliable antibodies for flow cytometry. Taken 
together, these results indicate that MAMPCs are morphologically 
and phenotypically closer to MAMs rather C-MOs from which 
they derive.
csF1r is required for MaMPcs to 
express TaM signature genes but  
not to accumulate in the Metastatic site
We next investigated whether MAMPCs require CSF1R signal 
that is known to be essential for the recruitment, differentiation, 
and survival of TAMs (5, 31, 32). Our microarray data suggest 
that CSF1R signaling is active in MAMPCs and the cells express 
transcripts for CSF1R regulated genes at higher abundance than 
C-MOs, as mRNA levels of direct effectors of CSF1R signaling 
pathway (i.e., Ets2 and Egr2) were fourfold higher in MAMPCs 
compared with C-MOs (Figure  4A). A recent study using a 
glioblastoma mouse model has identified ten signature genes 
whose expression in TAMs is regulated by CSF1R signaling, 
i.e., Adm1, Arg1, Cd163, Cdh1, F13a1, Hmox1, Il1r2, Mrc1, 
Serpinb2, and Stab1 (15). We thus examined our gene list to 
determine whether these CSF1R dependent TAM signature 
genes were upregulated in MAMPCs, and found that levels 
of six genes (Adm1, Arg1, Cd163, Cdh1, Hmox1, Il1r2, Mrc1, 
and Stab1) were significantly higher (logFC > 1.5, P < 0.01) in 
MAMPCs than C-MOs (Figure 4A). Expression of these genes 
were also higher in MAMs than C-MOs. To confirm the array 
data, we compared mRNA levels of the six genes in C-MOs 
from the blood, MAMPCs, MAMs, and RMACs from the lung 
of mice with metastatic tumors. We found that expression of 
Arg1, Hmox1, Mrc1, and Stab1 was significantly higher in 
MAMPCs than C-MOs and RMACs (Figure 4B). To investigate 
the involvement of CSF1R signaling in the expression of these 
genes, we utilized Csf1r conditional knockout (Csf1r-cKO) mice 
in which Csf1r gene is deleted by doxycycline treatment (21). 
The Csf1r-cKO and control C57BL/6 mice that have developed 
micro-metastases in the lung (Figure  2E) were treated with 
doxycycline for 1 week. These treatments significantly reduced 
CSF1R expression in C-MOs (the precursors of MAMPCs) in 
the Csf1r-cKO but not wild-type mice (Figure 4C). We found 
that almost all of the TAM signature genes except for Mrc1 were 
downregulated in MAMPCs as well as MAMs by loss of CSF1R 
(Figure 4D), suggesting that CSF1R signaling is necessary for 
MAMPCs to express MAM signature genes when they are dif-
ferentiated from circulating C-MOs.
We then asked whether the activation of CSF1R is required 
for the accumulation of MAMPCs in the metastatic site. As we 
expected, 1-week of treatment with doxycycline after microme-
tastasis formation significantly suppressed the accumulation of 
MAMs. However, the treatment did not reduce the number 
of MAMPCs or C-MOs (Figure  4E). Likewise, 1-week treat-
ment of tumor-injected C57BL/6 mice with a specific CSF1R 
antagonist BLZ945 reduced the number of MAMs in the 
lung without affecting the number of MAMPCs and C-MOs 
(Figure 4F). These results suggest that CSF1 signal is required 
for MAMPCs to acquire MAM-like phenotype whereas other 
signals might be involved in the full development of MAMPCs 
from C-MOs and their subsequent survival. Since MAMPCs 
continuously produce MAMs, a single treatment with CSF1R 
antagonist might not be sufficient in time or degree of inhibi-
tion to prevent metastatic tumor outgrowth. Consistently, the 
short-term blockade of CSF1R after micrometastasis formation 
showed negligible effects on the metastatic tumor expansion 
(Figures  4G,H), although long-term genetic MAM depletion 
through loss of Csf1 substantially inhibits metastasis (10).
MaMPcs suppress cytotoxicity of  
cD8+ T cells In Vitro
The phenotype of MAMPCs with CD11bhighLy6ChighLy6G− resem-
bles that of a subpopulation of MDSCs called monocytic MDSCs 
(M-MDSCs) (33). Since MDSCs and TAMs have been reported to 
suppress antitumor immune reaction in primary tumor models 
(11, 34, 35), we hypothesized that MAMPCs and MAMs in the 
metastatic site also possess immune suppressive phenotypes and 
thus performed an in vitro CD8+ T cell cytotoxicity assay. In this 
assay, we cultured E0771-LG cancer cells expressing red fluores-
cent protein (target) with splenic CD8+ T cells that were prein-
cubated with anti-CD3/CD28 antibodies (effector), and detected 
tumor cell apoptosis indicated by green fluorescence from a 
FigUre 4 | Colony-stimulating factor 1 (CSF1) signaling is required for tumor-associated macrophage (TAM) signature gene expression in metastasis-associated 
macrophage precursor cells (MAMPCs) but is not essential for their accumulation in the metastatic site. (a) Fold-change of genes encoding transcription factors 
(TFs) and TAM-signature genes (15) under CSF1 receptor (CSF1R) control determined by microarray analyses in Figure 3. Graphs show genes whose expression 
was higher in MAMPCs and MAMs than classical monocytes (C-MOs) (logFC > 1, FDR < 0.05). Data on expression values are presented as mean ± SEM. Note 
that the scale is exponential. (B) Relative mRNA expression assessed by quantitative RT-PCR in C-MOs (green), MAMPCs (blue), MAMs (red), and resident 
macrophages (RMACs) (Purple) (n = 3, two independent experiments). C-MOs were isolated from blood, and MAMPCs, MAMs, and RMACs were isolated from the 
metastatic lung of mice injected with E0771-LG cells. Data are mean ± SEM, *P < 0.05 vs. C-MO. (c) Mean fluorescence intensity of CSF1R in circulating C-MOs 
from tumor-bearing C57BL/6 (wild type) and CSF1R conditional knockout (Csf1r cKO) mice treated with doxycycline from day 7 to day 14 after intravenous injection 
of E0771-LG cells (n = 3, two independent experiments). Data are mean ± SEM, *P < 0.01. (D) Relative mRNA expression assessed by real time RT-PCR in 
MAMPCs and MAMs isolated from the metastatic lung of wild-type and Csf1r cKO mice that were treated as described above (n = 3, two independent 
experiments). Data are mean ± SEM, *P < 0.05. (e) Relative numbers of C-MOs in the blood, and MAMPCs and MAMs in the metastatic lung of Csf1r cKO mice 
treated with doxycycline (Dox) or vehicle (Veh) as described above (n = 3/group, two independent experiments). Data are mean ± SEM, *P < 0.01. (F) Relative 
numbers of C-MOs in the blood, and MAMPCs and MAMs in the metastatic lung of C57BL/6 mice treated with BLZ945, a selective CSF1R antagonist (BLZ) or Veh 
from day 7 to day 14 after intravenous injection of E0771-LG cells (n = 3/group, two independent experiments). Data are mean ± SEM, *P < 0.01. (g) Lung 
metastatic burden quantified as a metastasis index that is equal to total metastasis volume normalized by total lung volume. Csf1r cKO mice were treated with Dox 
or Veh from day 7 to day 14 after intravenous injection of E0771-LG cells (n = 6/group, two independent experiments). Data are mean ± SEM, *P < 0.01. (h) Lung 
metastatic burden quantified by bioluminescence imaging. C57BL/6 mice were treated with BLZ945 (BLZ) or Veh from day 7 to day 14 after intravenous injection of 
E0771-LG cells (n = 3/group, two independent experiments). Data are mean ± SEM, *P < 0.01.
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fluorogenic caspase-3 substrate by microscopy (Figure 5A). As 
shown in Figure 5B, tumor cell apoptosis (i.e., number of red/
green double positive cells) was induced by preactivated CD8+ 
T  cells and enhanced in accordance with increased effector to 
target (E:T) ratios.
To test our hypothesis, we isolated MAMPCs, MAMs, and 
RMACs from the lung with metastatic E0771-LG tumors and 
cultured with splenic CD8+ T cells in the presence of anti-CD3/
CD28 activating antibodies. We then isolated the CD8+ T cells 
and evaluated their cytotoxicity against E0771-LG cells. The 
CD8+ T cells cocultured with MAMPCs or MAMs showed sig-
nificantly lower cytotoxicity compared with the cells without the 
coculture (Figures 5A,B). Although the CD8+ T cell cytotoxicity 
was also somewhat reduced by RMACs, their suppressive effect 
FigUre 5 | Metastasis-associated macrophage (MAM) precursor cells (MAMPCs) suppress cytotoxicity of CD8+ T cells through a reactive oxygen species 
(ROS)-mediated mechanism. (a,B) Effects of myeloid cells on the CD8+ T cell-induced tumor cell apoptosis. Splenic CD8+ T cells from normal C57BL/6 mice were 
cultured with anti-CD3/CD28 antibodies (effector; E) in the absence or presence of MAMPCs, MAMs, or resident macrophages (RMACs) from the metastatic lung of 
E0771-LG-injected mice (MAMPC/E, MAM/E, RMAC/E, respectively). The preincubated T cells were then isolated and cultured with E0771-LG cells expressing red 
fluorescent protein in the nuclei (target; T) at the indicated E:T ratio in the presence of green fluorogenic caspase-3 substrate. After 36 h, the number of apoptotic 
cancer cells indicated by red/green double positive nuclei was counted. (a) Representative images of cells cultured with the caspase-3 substrate for 36 h (E:T = 4:1). 
Scale bar; 50 µm, arrowhead; apoptotic cancer cell. (B) Number of apoptotic cancer cells cultured with preactivated CD8+ T cells (n = 3, two independent 
experiments). Data are mean ± SEM, *P < 0.01 vs. E + T (4:1), #P < 0.01 vs. MAMPC/E + T. (c) Fold-change of genes encoding checkpoint T cell receptor ligands 
in MAMPCs and MAMs compared with classical monocytes (C-MOs) determined by microarray analyses in Figure 3 (logFC > 1, FDR < 0.05). Data on expression 
values are presented as mean ± SEM. Note that the scale is exponential. (D) Mean fluorescence intensity of checkpoint T cell receptor ligands assessed by flow 
cytometry in C-MOs, MAMPCs, and MAMs (n = 3, two independent experiments). Blood (for C-MOs) and lung digestion (for MAMPCs and MAMs) were prepared 
from E0771-LG-injected C57BL/6 mice at 14 days posttumor injection and stained with antibodies for indicated markers or isotype IgG. Data are mean ± SEM, 
*P < 0.01 vs. IM, #P < 0.01 vs. MAMPC. (e) Effects of checkpoint inhibitors on the suppressive activity of MAMPCs and MAMs (n = 6, two independent 
experiments). CD8+ T cells were cultured with anti-CD3/CD28 antibodies and neutralizing antibodies for PD1 or CTLA4, or isotype IgG in the absence (effector; E) or 
presence of MAMPCs (MAMPC/E) or MAMs (MAM/E). Cytotoxicity of the precultured CD8+ T cells against E0771-LG cells at 4:1 E/T ratio were assessed as 
described above. Data are mean ± SEM that represent the ratio in number of apoptotic cancer cells relative to that induced by CD8+ T cells cultured with IgG in the 
absence of MAMPCs or MAMs (control). *P < 0.01 vs. control, #P < 0.01 vs. IgG. (F) Effects of inhibitors of nitric oxide or ROS production on the suppressive activity 
of MAMPCs and MAMs (n = 6, two independent experiments). CD8+ T cells were cultured with anti-CD3/CD28 antibodies and L-NMMA, nor-NOHA, catalase and 
superoxide dismutase (SOD) (Cat/SOD), or vehicle (–) in the absence (e) or presence of MAMPCs (MAMPC/E) or MAMs (MAM/E). Cytotoxicity of the precultured 
CD8+ T cells against E0771-LG cells at 4:1 E/T ratio were assessed as described above. Data are mean ± SEM that represent the ratio of apoptotic cancer cells 
relative to that induced by CD8+ T cells cultured with PBS in the absence of MAMPCs or MAMs (control). *P < 0.01 vs. control, #P < 0.01 vs. PBS.
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was significantly lower than MAMPCs or MAMs. Unfortunately 
we could not investigate suppressive effects of C-MOs due to the 
low number of cells collectible from the blood of tumor-bearing 
mice for this assay. Nevertheless and of importance, our data indi-
cate that within the metastatic tissue MAMs and their immediate 
progenitors are immunosuppressive.
Our array data (Figure  5C) indicated that MAMPCs and 
MAMs compared with C-MOs expressed higher levels of mRNA 
coding PD-L1 (Cd274), PD-L2 (Pdcd1lg2), CD80, and CD86 
that negatively regulate CD8+ T cell responses upon binding to 
checkpoint receptors, programmed cell death protein 1 (PD-1) 
and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) (36). 
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Flow cytometry confirmed that MAMPCs and MAMs expressed 
higher levels of PD-L1, PD-L2, and CD80 proteins compared 
with circulating C-MOs, whereas CD86 was expressed only 
MAMs (Figure  5D). We thus investigated their contributions 
to the CD8+ T cell suppression using antibodies against PD1 or 
CTLA4. Anti-CTLA4 blocking antibody partly but significantly 
increased the cytotoxicity of CD8+ T cell suppressed by MAMs 
whereas anti-PD1 antibody did not affect the suppressive activity 
of MAMs (Figure 5E), suggesting that CD80/CD86 expression 
on MAMs (Figure 5D) might have a role in the MAM-induced 
suppression. On the other hand, neither PD1 nor CTLA4 inhibi-
tion reversed the MAMPC-induced CD8+ T  cell suppression 
(Figure 5E), suggesting that checkpoint receptors play a minor 
role in the suppressive mechanism of MAMPCs if any. We then 
investigated whether the MAMPC-induced suppression is medi-
ated by arginase-1, inducible nitric oxide synthase (iNOS), and 
ROS that are key factors for MDSCs to exert immune suppressive 
activity (37). As shown in Figure 5F, combination of superoxide 
dismutase (SOD) and ROS-scavenging enzyme catalase signifi-
cantly reversed the CD8+ T cell paralysis induced by MAMPCs, 
whereas this inhibition was not reversed by the iNOS inhibitor 
L-NMMA nor the arginase inhibitor NOHA. These results suggest 
that MAMPCs suppress CD8+ T cell cytotoxicity at least partly 
by a ROS-mediated but not by a nitric oxide (NO)-mediated 
mechanism. In contrast, these inhibitors had no influence in the 
MAM-mediated CD8+ T cell suppression (Figure 5F).
Taken together, this study identified a distinct population of 
MAM precursor in the metastatic sites that accumulate during 
the metastatic tumor growth by CSF1R independent mechanism, 
and suppress CD8+ T  cell cytotoxicity by a ROS-mediated but 
checkpoint receptor-independent mechanism.
DiscUssiOn
Myeloid cells such as macrophages, neutrophils, and MDSCs 
are known to accumulate in the tumor microenvironment and 
to actively promote the metastatic process (4). Using metastatic 
breast cancer models in mice, we have reported that MAMs, a 
distinct population of macrophages, abundantly accumulate in 
the tumor-challenged lung where they promote extravasation 
and survival of metastatic cancer cells (10). We have also identi-
fied that C-MOs preferentially migrate to the metastatic tumors 
and differentiate into MAMs (20). However, the fate and charac-
teristics of the C-MOs after their migration into the metastatic 
site has not been elucidated.
Using a monocyte tracking method, we have identified here 
that circulating C-MOs (CD11b+Ly6C+) differentiate into a 
distinguishable myeloid cell population characterized by being 
CD11bhighLy6Chigh immediately after migrating to the metastatic 
lung. Since the CD11bhighLy6Chigh cells shift over time into a gate 
of MAMs (CD11bhighLy6Clow) in the metastatic site, these cells 
can be identified as MAMPCs. Although C-MOs differentiate to 
CD11b+Ly6Clow (NC-MOs) in the blood, these cells were distinct 
from the CD11bhighLy6Clow MAMs by their lower expression of 
CD11b, F4/80, and MHC-II. Since C-MOs preferentially migrate 
to the metastatic lung than NC-MOs (20), the majority of MAMs 
in the lung are differentiated from C-MOs through MAMPCs, 
although our data does not exclude a minor contribution of 
NC-MOs recruited to the metastatic site or tissue-RMACs of 
embryonic origin as suggested by recent studies (38, 39).
Accumulation of the CD11bhighLy6Chigh cells was found 
in the lung with metastatic mammary tumors developed by 
E0771-LG or Met-1 cells experimentally and by PyMT transgene 
spontaneously. Although the number of CD11bhighLy6Chigh cells 
in the spontaneous model (PyMT) was lower than that in the 
experimental model (E0771), it is probably because PyMT mice 
on C57BL/6 background develop lower numbers and smaller 
tumors (0.3 ± 0.2 foci/mm2 lung, 0.3 ± 0.2 mm diameter/foci) 
compared with E0771-injected C57BL/6 mice (1.0 ± 0.3 foci/mm2 
lung, 0.5 ± 0.1 mm diameter/foci, P < 0.01). Consistent with this 
interpretation, the number of the Ly6Chigh cells in the experimen-
tal model correlated with tumor load in the lung. These results 
suggest that accumulation of the CD11bhighLy6Chigh MAMPCs in 
the metastatic site is a common feature of breast cancer models 
in mice. Consistent with these data, a recent study has reported 
that CD11b+Ly6Chigh cells are recruited to the lung with metastatic 
tumors developed by 4T1 mouse mammary tumor cells (40).
Metastasis-associated macrophage precursor cells are clearly 
distinguished from C-MOs or MAMs by their high CD11b and 
Ly6C expression as well as by their gene expression profile. Their 
low Ly6G expression excludes the possibility that they are neutro-
phils, as does their morphology. On the other hand, the phenotype 
of MAMPCs with CD11bhighLy6ChighLy6G− resembles that of a 
subpopulation of MDSC called M-MDSCs (33). A recent report 
has proposed three criteria to identify cells as MDSCs; a popula-
tion of cells (i) expanded compared with normal conditions, (ii) 
have typical phenotype of MDSCs (CD11b+Ly6ChiLy6G− for 
M-MDSC in mice) and (iii) possesses immune suppressive 
activity (33). We have shown that the MAMPCs are character-
ized as CD11b+Ly6ChiLy6G−, expand in the lung with metastatic 
tumors compared with the normal lung, and suppress CD8+ 
T cell cytotoxicity in vitro. Therefore, the MAMPCs accumulate 
in the metastatic lung of breast cancer models can be identified 
as M-MDSCs.
Monocytic MDSCs have been defined as myeloid cells that 
are distinct from mature myeloid cells such as macrophages and 
neutrophils, but are morphologically and phenotypically similar 
to monocytes (34). In our model, the majority of MAMPCs in 
the metastatic lung had a larger cytoplasm containing vacuoles, 
which is clearly distinct from typical monocyte morphology but 
similar to MAMs, suggesting that M-MDSCs in the metastatic 
sites (i.e., MAMPCs) are committed to macrophage lineage com-
pared with circulating C-MOs. Consistent with these data, the 
gene expression profile of MAMPCs was closer to that of MAMs 
than C-MOs, and the majority of MAMPCs expressed high levels 
of mature macrophage markers such as CD14, CD36, CD64, and 
CD206. Compared with C-MOs, MAMPCs expressed higher 
levels of TAM signature genes (i.e., Arg1, Cdh1, Hmox1, Il1r2, 
Mrc1, and Stab1) that were also highly expressed by MAMs, sug-
gesting that differentiation of C-MOs to MAMPCs (M-MDSCs) 
is directed toward the tumor-promoting macrophages. Since 
circulating C-MOs expressed much lower levels of these mac-
rophage markers compared with MAMPCs and only very minor 
population of C-MOs (6.5%) showed the MAMPC-like mor-
phology with cytoplasmic vacuoles, differentiation of C-MOs to 
M-MDSCs occurs mainly in the metastatic sites. Since these cells 
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accumulate in the metastatic tissue, this suggests that the rate of 
C-MO recruitment by high CCL2 (20) and their differentiation 
into MAMPCs exceeds the rate of MAMPC differentiation into 
MAMs, although the monocyte tracking experiment indicates 
that they will all do so eventually.
It has been reported that CD11b+Gr-1+ MDSCs transferred 
into the mice with C3 fibrosarcoma or EL4 lymphoma reduce 
their Gr1 (Ly6C/Ly6G) expression and express a macrophage 
marker F4/80 (41, 42). These results suggest that M-MDSCs can 
differentiate into TAMs in the tumor microenvironment, whereas 
the fate of M-MDSCs in the metastatic tumor microenvironment 
has not been fully identified. Our study shows direct evidence 
that the CD11bhighLy6Chigh M-MDSCs originate from C-MOs and 
differentiate into MAMs (CD11bhighLy6Clow) in the metastatic site. 
Consistent with our data, treatment of 4T1 tumor-bearing mice 
with all trans retinoic acid reduces the number of CD11b+Gr-1+ 
cells and concomitantly increases the number of CD11b+Gr-
1−F4/80+ cells in the metastatic lung (43).
In this 4T1 tumor model, both Gr-1+ cells and F4/80+ cells 
from the metastatic lung have ability to suppress T  cell prolif-
eration and their cytokine secretion whereas the suppressive 
effects are stronger in F4/80+ cells than Gr-1+ cells, suggesting 
that MAMs are more potent immune suppressors than MDSCs 
(43). In contrast, our data indicate that CD11bhighLy6Chigh cells 
(M-MDSCs/MAMPCs) and CD11bhighLy6Clow cells (MAMs) 
suppress cytotoxicity of preactivated CD8+ T cells at comparable 
levels. This discrepancy can be explained by heterogeneity of 
MDSCs in the former experiment, i.e., Gr-1+ cells include not 
only M-MDSCs (CD11b+Ly6ChighLy6G−) but also include less 
immune suppressive PMN-MDSCs (CD11b+Ly6ClowLy6G+) 
since anti-Gr-1 antibody recognizes both Ly6C and Ly6G (44). 
As anti-Ly6C antibody does not cross react with Ly6G, it is more 
specific to M-MDSCs. Consequently, our data suggest that both 
MAMs and their progenitor MAMPCs are potent immune sup-
pressors in the metastatic tumors.
In our metastatic breast cancer model utilizing E0771-LG 
cells, suppression of CD8+ T  cell cytotoxicity by MAMPC 
(M-MDSC) was reversed by a combination of catalase and 
SOD but not by L-NMMA, suggesting that M-MDSCs in the 
metastatic site of breast cancer use ROS rather than NO to 
suppress T  cell functions. Consistent with these data, similar 
results were observed in 4T1 metastatic breast cancer model, 
i.e., T cell suppression by CD11b+Gr1+ MDSCs from metastatic 
lung was restored by catalase but not by L-NMMA (43). On the 
other hand, M-MDSCs isolated from the ascites or spleen of 
EL4 lymphoma-injected mice were reported to suppress T cell 
functions largely by production of NO and/or reactive nitrogen 
species (42, 44, 45). These results suggest that M-MDSCs might 
utilize different suppressive mechanisms in response to the 
tumor microenvironment that are determined by tumor types 
and location. Our results also suggest that MAMs and MAMPCs 
utilize different mechanism to suppress CD8+ T cell cytotoxicity, 
as inhibitors for ROS or NO production had no influence in the 
MAM-mediated CD8+ T  cell suppression. Given the diversity 
and plasticity of suppressor myeloid cells, a combination of 
inhibitors might therefore be needed to block the immunosup-
pressive tumor microenvironment.
In a mouse model of pancreatic cancer, inhibition of CSF1R 
signaling suppresses TAMs accumulation and their immune 
suppressive functions, and thereby synergize with checkpoint-
blockade immunotherapy (13). Given the effects of BLZ945 and 
anti-CTLA4 antibody on MAM functions in our model, the 
combination of CSF1R antagonist and checkpoint inhibitor may 
also be effective for metastatic breast cancer. On the other hand, 
our results suggest that MAMPCs, another immunosuppressive 
compartment in the metastatic site, might not be targeted by 
this strategy. Interestingly, it has suggested that accumulation 
of MDSCs requires two sets of signals that are largely mediated 
by tumor and tumor stromal cell-derived growth factors (e.g., 
GM-CSF, etc.) and proinflammatory cytokines (e.g., IL-6, etc.) 
(34). A recent study also shows that high mobility group box 1 
(HMGB1) secreted from human breast cancer cells induces dif-
ferentiation of monocytes into M-MDSCs and their survival (46, 
47), suggesting that these cytokines will be potential therapeutic 
targets to prevent MAMPC accumulation and further improve 
immunotherapy effects metastatic breast cancer.
This study shows, to our knowledge for the first time, that 
MAMs are differentiated from a distinct population of precursor 
cells (MAMPCs) that phenotypically represent the cells originally 
described as M-MDSCs, and prevent T cell cytotoxicity at least 
in vitro. Characteristics of the MAMPCs identified in this study 
highlight the importance of further investigation of mechanisms 
behind their development in the metastatic site, which will lead 
to a novel and effective strategies to improve immunotherapy for 
metastatic breast cancer.
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